Fig. 1 · Structure

Documents & Downloads

Necrostatin-1

Cat. No. A11973 CAS 4311-88-0

RIPK1 inhibitor

Necrostatin-1 is an ATP-competitive, allosteric inhibitor of receptor-interacting protein kinase 1 (RIPK1) (EC50 = 182 nM).

In Stock

Publications for Necrostatin-1

2 publications citing this product

  1. Cheng Chen, .et al. , Neurochem Res, 2025, Mar 18;50(2):122 PMID: 40100474
  2. Binjie Yan, .et al. , Cell Death Discov, 2023, 9: 456 PMID: 38097554

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Necrostatin-1 inhibits RIPK1 (RIP1) kinase activity. Biochemical assays and RIP1 reconstitution experiments support RIPK1 as a functional cellular target. T-loop mutations reduced sensitivity, supporting the reported conformation-dependent, allosteric interpretation; the proposed binding pose was a model rather than a measured parent-compound structure. [1]

Parent Necrostatin-1 also inhibited recombinant human IDO. The demethylated comparator Nec-1i retained IDO activity, whereas the distinct stable analogue Nec-1s did not in that assay. Parent Nec-1 therefore requires target-specific controls when attributing biological effects to RIPK1. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
RIP1 (293T cells) EC50 490 nM

Cellular Effect

Cell Line Activity Value Description Reference
Jurkat IC50 494 nM Inhibition of death receptor signaling mediated necroptotic cell death in human Jurkat cell deficient in FADD assessed as cell viability after 30 hrs by ATP based viability assay in presence of TNFalpha [PMID: 16408008]
Sf9 IC50 182 nM Inhibition of recombinant human GST-fused RIPK1 (1 to 497 residues) expressed in baculovirus infected insect Sf9 cells in presence of 32P-gamma-ATP after 30 mins by autoradiogram-based Western blot method [PMID: 28280261]

Necrostatin-1 Research Summary

This section summarizes 4 in vitro studies and 2 in vivo studies of Necrostatin-1 from 4 published references. In vitro models include primary rat aortic smooth muscle cells from Sprague-Dawley rats.

Necrostatin-1 In Vitro Studies

In RIP1-deficient Jurkat cells reconstituted with wild-type RIP1, 30 μM Necrostatin-1 suppressed induced necroptotic death. The S161E and F162E variants markedly reduced this inhibition, providing cellular evidence for the RIP1 target assignment. [1]

Necrostatin-1 did not rescue MTT viability in primary rat aortic smooth muscle cells exposed for 24 h to MI-2 or erastin at the tested 10 μM Nec-1 concentration. Ferrostatin-1 and deferoxamine rescued viability in parallel. The paper identifies its Nec-1 reagent as Adooq A11973. [3]

RIP1 autophosphorylation inhibition and biochemical controls

Biochemical assay · Immunoprecipitated human RIP1 from HEK293T or Jurkat cells; recombinant human RIP1 as an additional direct-inhibition check [1]

Nec-1 inhibited RIP1 autophosphorylation. Kinase-inactive K45M, RIP1-deficient cells, protein-loading controls and the less active demethylated analogue supported assignment of the assay signal and compound effect. Recombinant RIP1 was also inhibited.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
RIP1 autophosphorylationQualitative inhibition with biochemical controls Concentration-dependent inhibition; analogue 5 substantially less active. Representative assays repeated at least two or three times, with similar results.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Figure 1c: 1, 10 and 100 μM; Figure 1e: 3 and 30 μM; recombinant assay Figure 2d: 30 and 100 μM
Exposure duration
15-min inhibitor preincubation; 30-min kinase reaction
Method
Radiolabelled ATP autophosphorylation assay; SDS-PAGE and autoradiography
Vehicle
3% DMSO in the kinase assay
Reported limits
No new IC50 is calculated; the SI dose-response material supporting the text-reported potency was not acquired.
Methods and source locations

Compound reported in the paper: Necrostatin-1; Compound label in the paper: 1

Reported parent-compound experiment; no assumption of current Adooq lot equivalence, salt conversion or enantiomer-specific activity.

Results, Nec-1 is a RIP1 kinase inhibitor in vitro; Figures 1b–e and 2d–e; Chemical compounds and In vitro kinase assay

RIP1 autophosphorylation: Autoradiography with parallel RIP1 immunoblot controls — Figures 1b–e, 2d–e and corresponding Results

Cellular RIP1 target validation with T-loop mutants

Cell-based study · RIP1-deficient human Jurkat cells reconstituted with wild-type RIP1 or S161A, S161E and F162E variants [1]

Nec-1 suppressed induced death in cells reconstituted with wild-type RIP1, whereas S161E and F162E markedly attenuated inhibition. Equal-expression controls support cellular target assignment. Mutants still required the receptor stimulus to induce death.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell death with wild-type versus mutant RIP1, with and without Nec-1Cellular target validation Inhibition attenuated with T-loop mutants, particularly S161E and F162E; one experiment in triplicate, mean ± s.d.; repeated multiple times with similar results.[1]

Literature-Reported Treatment Conditions

Treatment concentration
30 μM Nec-1
Exposure duration
24-h death-induction assay after 48-h recovery from reconstitution
Method
Flow cytometry of GFP-positive, propidium-iodide-negative cells
Co-treatment
Agonistic Fas antibody, cycloheximide and zVAD-fmk used to induce necroptosis; CHX + zVAD without Fas was a control.
Reported limits
Cellular vehicle fraction is not specified for this comparison. Co-stimulus doses are not transcribed because the retained manuscript has problematic unit typography.
Methods and source locations

Compound reported in the paper: Necrostatin-1; Compound label in the paper: 1

Reported parent-compound experiment; no assumption of current Adooq lot equivalence, salt conversion or enantiomer-specific activity.

Results, RIP1 T-loop controls inhibition by Nec-1; Figure 3e and accompanying immunoblots; RIP1 reconstitution in RIP1-deficient Jurkat cells

Cell death with wild-type versus mutant RIP1, with and without Nec-1: FACS viability analysis; RIP1/tubulin immunoblots for expression controls — Figure 3e caption, plot and Results paragraph following Figure 3

IDO activity reveals an additional target of parent Nec-1

Biochemical assay · Purified recombinant human indoleamine 2,3-dioxygenase (IDO), with L-tryptophan substrate [2]

Nec-1 and Nec-1i inhibited IDO activity, whereas Nec-1s did not in the tested range. The 1-methyltryptophan comparator also inhibited IDO. Thus the parent compound cannot be treated as exclusively RIPK1-directed.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Human IDO enzyme activityQualitative concentration-response comparison Nec-1 and Nec-1i inhibited IDO; Nec-1s showed no inhibition in the tested assay. 1-MT served as an active IDO comparator.[2]

Literature-Reported Treatment Conditions

Treatment concentration
Three-fold serial dilutions from 100 μM to 1.69 nM
Exposure duration
60-min enzymatic reaction at 37 °C
Method
Kynurenine colorimetric endpoint at 490 nm
Co-treatment
100 μM L-tryptophan substrate
Reported limits
Vehicle fraction and replicate-number semantics for Figure 4a are not specified in its caption or IDO Methods. No fitted EC50 value is transcribed.
Methods and source locations

Compound reported in the paper: Necrostatin-1; Compound label in the paper: Nec-1

Reported parent-compound experiment; no assumption of current Adooq lot equivalence, salt conversion or enantiomer-specific activity.

Results, Nec-1 and Nec-1i, but not Nec-1s, inhibit IDO enzyme activity; Figure 4a; IDO enzymatic assay; Cells, cytokines and reagents

Human IDO enzyme activity: Colorimetric measurement of kynurenine formation — Figure 4a and IDO enzymatic assay

Nec-1 fails to rescue viability in two ferroptosis-associated SMC conditions

Cell-based study · Primary rat aortic smooth muscle cells from Sprague-Dawley rats [3]

Nec-1 did not rescue the loss of MTT viability induced by MI-2 or erastin. Ferrostatin-1 and deferoxamine rescued viability in the same comparison. This is a model-specific negative result, not evidence of a general absence of Nec-1 activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MTT viability after MI-2 or erastin, with or without cell-death inhibitorsNegative rescue result No rescue by Nec-1; rescue by Fer-1 or DFO. Figure caption n=4; mean ± SEM per Methods. Methods state at least three independent experiments unless otherwise stated; wells were plated in triplicate.[3]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM Nec-1
Exposure duration
24 h
Method
Co-treatment; MTT viability assay
Co-treatment
MI-2 1 μM or erastin 5 μM; parallel comparator treatments included Fer-1 5 μM, DFO 100 μM, Z-VAD-fmk 25 μM and Z-YVAD-fmk 10 μM.
Reported limits
Exact vehicle composition/final concentration for this cell comparison is not specified in the selected text. No exact viability percentage is inferred from the bars.
Methods and source locations

Compound reported in the paper: Necrostatin-1; Compound label in the paper: Nec-1

Reported parent-compound experiment; no assumption of current Adooq lot equivalence, salt conversion or enantiomer-specific activity.

Results, Treatment with MI-2 induces ferroptotic cell death in aortic SMCs; Figure 1B–C; Reagents and Antibodies; Cell culture; MTT assay; Statistical analysis

MTT viability after MI-2 or erastin, with or without cell-death inhibitors: MTT assay, absorbance at 595 nm — Figure 1B–C with caption; first Results subsection; Statistical analysis

Necrostatin-1 In Vivo Studies

In a mouse TNF-challenge model, Necrostatin-1 showed a non-monotonic response: higher doses were protective, whereas 0.6 mg/kg worsened hypothermia and survival. Nec-1i also protected at higher doses and was unsuitable as an inert comparator in this setting. These findings limit simple dose and specificity assumptions. [2]

An intravenous 1.65 mg/kg Necrostatin-1 bolus at reperfusion reduced myocardial infarct size in wild-type mice. It produced no significant additional reduction in cyclophilin-D-knockout mice. The result supports a context-dependent protective effect and does not establish direct binding to the mitochondrial permeability transition pore. [4]

Non-monotonic Nec-1 response in mouse TNF challenge

Animal study · Female C57BL/6J wild-type mice, 8–14 weeks; TNF-induced systemic inflammatory response model [2]

Nec-1 protected against hypothermia and mortality at higher doses but sensitized mice at 0.6 mg/kg. Nec-1i was also protective at higher doses, so it was not an inert in vivo comparator. The cause of the low-dose adverse response was unresolved.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Hypothermia and survival following TNF challengeDose-dependent direction of effect Protection at 6 and 3 mg/kg; sensitization at 0.6 mg/kg. Figure 5a–d pool two independent experiments. Temperature: mean ± S.E.M.; survival compared by log-rank Mantel–Cox test.[2]

Conditions shared by the study groups

Route
Intravenous
Frequency
Single pretreatment
Treatment course
17 min before 7.5 μg intravenous mouse TNF
Vehicle
6% DMSO in PBS, matched vehicle control
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Nec-1 dose series
6, 3 or 0.6 mg/kg body weight
DMSO + TNF; matched Nec-1i dose series6 and 3 mg/kg were protective; 0.6 mg/kg accelerated hypothermia and reduced survival. Figure 5d Nec-1 Hi/Mo/Lo n=5/11/10; DMSO n=11; Nec-1i Hi/Mo/Lo n=5/11/10.[2]
Nec-1 dose series
Model: Female C57BL/6J wild-type mice, 8–14 weeks; TNF-induced systemic inflammatory response model
Methods and source locations

Compound reported in the paper: Necrostatin-1; Compound label in the paper: Nec-1

Reported parent-compound experiment; no assumption of current Adooq lot equivalence, salt conversion or enantiomer-specific activity.

Results section 6; Figure 5c–d and caption; Mice, Injections and monitoring, Statistical analysis

Hypothermia and survival following TNF challenge: Serial body temperature and survival monitoring — Figure 5c–d, Results section 6 and Statistical analysis

Nec-1 dose series · Figure 5c–d and caption; Results section 6; Mice; Injections and monitoring

Cardiac infarct reduction depends on mouse genotype

Animal study · Male wild-type B6129SvF1 and cyclophilin-D-knockout mice, 8–10 weeks, 20–30 g; myocardial ischemia/reperfusion [4]

Nec-1 reduced infarct size in wild-type mice but produced no significant additional reduction in cyclophilin-D-deficient mice. Areas at risk were comparable. This genotype interaction does not establish direct MPTP binding or prove that every protective effect is mediated solely through RIPK1.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Infarct size as percentage of area at risk, wild-type miceMean ± SEM Nec-1 17.7 ± 3% versus vehicle 54.3 ± 3%; P < 0.05; Figure 1 caption n = 5–6.[4]
Infarct size as percentage of area at risk, cyclophilin-D-knockout miceMean ± SEM Nec-1 28.3 ± 7% versus vehicle 30.8 ± 6%; P > 0.05; Figure 1 caption n = 5–6.[4]

Conditions shared by the study groups

Route
Intravenous
Frequency
Single bolus
Treatment course
At onset of reperfusion; assessment after 120 min reperfusion
Vehicle
0.2% DMSO
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Wild-type comparison
1.65 mg/kg
Genotype-matched 0.2% DMSO vehicleInfarct size reduced versus vehicle (17.7 ± 3% versus 54.3 ± 3%, mean ± SEM).[4]
Cyclophilin-D-knockout comparison
1.65 mg/kg
Genotype-matched 0.2% DMSO vehicleNo significant additional infarct reduction (28.3 ± 7% versus 30.8 ± 6%, mean ± SEM; P > 0.05).[4]
Wild-type comparison
Model: Male B6129SvF1 wild-type mice
Cyclophilin-D-knockout comparison
Model: Male cyclophilin-D-knockout mice
Methods and source locations

Compound reported in the paper: Necrostatin-1; Compound label in the paper: Nec-1

Reported parent-compound experiment; no assumption of current Adooq lot equivalence, salt conversion or enantiomer-specific activity.

Animals; In vivo model of ischemia reperfusion injury; Chemicals; Statistical Analysis; Results; Figure 1A–B; Discussion

Infarct size as percentage of area at risk, wild-type mice: Evans blue/triphenyltetrazolium dual staining; one-way ANOVA with Tukey multiple comparisons — Results paragraph and Figure 1B caption; Statistical Analysis

Infarct size as percentage of area at risk, cyclophilin-D-knockout mice: Evans blue/triphenyltetrazolium dual staining; one-way ANOVA with Tukey multiple comparisons — Results paragraph and Figure 1B caption; Statistical Analysis

Wild-type comparison · Methods; Results; Figure 1B

Cyclophilin-D-knockout comparison · Methods; Results; Figure 1B

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 4311-88-0
Applications RIPK1 inhibitor
Formula C13H13N3OS
Molecular Weight 259.33
SMILES
CN1C(=O)C(NC1=S)CC2=CNC3=CC=CC=C32

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 43 mg/mL (165.81 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
5% DMSO+45% PEG 300+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

From the Knowledge Base

Browse all articles

Necrostatin-1 Research References

  1. [1] Alexei Degterev, Junichi Hitomi, Megan Germscheid, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins Nature Chemical Biology (2008). PMID: 18408713 DOI: 10.1038/nchembio.83 Source material
  2. [2] Takahashi N, Duprez L, Grootjans S, et al. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models Cell Death & Disease (2012). PMID: 23190609 DOI: 10.1038/cddis.2012.176 Source material
  3. [3] Yan Binjie, Belke Darrell, Gui Yu, et al. Pharmacological inhibition of MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) induces ferroptosis in vascular smooth muscle cells Cell Death Discovery (2023). PMID: 38097554 DOI: 10.1038/s41420-023-01748-9 Source material
  4. [4] SY Lim, SM Davidson, MM Mocanu, et al. The cardioprotective effect of necrostatin requires the cyclophilin-D component of the mitochondrial permeability transition pore Cardiovascular Drugs and Therapy (2007). PMID: 17965927 DOI: 10.1007/s10557-007-6067-6 Source material

Publications

2 publications citing this product

  1. Cheng Chen, .et al. , Neurochem Res, 2025, Mar 18;50(2):122 PMID: 40100474
  2. Binjie Yan, .et al. , Cell Death Discov, 2023, 9: 456 PMID: 38097554

Added to your cart

View Cart Checkout
Loading...